Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

Patent metadata

Field	Value
Publication number	US-10272083-B2
Application number	US-201515112968-A
Country	US
Kind code	B2
Filing date	Jan 21, 2015
Priority date	Jan 21, 2014
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.

First claim

We claim:

1. A method of treating chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) in a human subject suffering therefrom, comprising the step of orally administering, to the human subject, a dose of 100 mg twice daily of a Bruton's tyrosine kinase (BTK) inhibitor, wherein the BTK inhibitor is a compound of Formula (II):

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2. The method of claim 1 , wherein the BTK inhibitor is a compound of Formula (II):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the BTK inhibitor is administered to the human subject for a period selected from the group consisting of about 14 days, about 28 days, and about 56 days.

4. The method of claim 2 , wherein the CLL is selected from the group consisting of IgV H mutation negative CLL, ZAP-70 positive CLL, ZAP-70 methylated at CpG3 CLL, CD38 positive CLL, CLL with a 17p13.1 (17p) deletion, CLL with a 11q22.3 (11q) deletion, CLL in a human sensitive to platelet-mediated thrombosis, CLL in a human presently suffering from platelet-mediated thrombosis, CLL in a human previously suffering from platelet-mediated thrombosis, and combinations thereof.

5. The method of claim 2 , further comprising the step of administering a therapeutically effective dose of an anti-CD20 antibody selected from the group consisting of rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, ibritumomab, and fragments, derivatives, conjugates, variants, radioisotope-labeled complexes, and biosimilars thereof.

6. The method of claim 2 , further comprising the step of administering a therapeutically effective dose of an anticoagulant or antiplatelet active pharmaceutical ingredient.

7. The method of claim 6 , wherein the anticoagulant or antiplatelet active pharmaceutical ingredient is selected from the group consisting of acenocoumarol, anagrelide, anagrelide hydrochloride, abciximab, aloxiprin, antithrombin, apixaban, argatroban, aspirin, aspirin with extended-release dipyridamole, beraprost, betrixaban, bivalirudin, carbasalate calcium, cilostazol, clopidogrel, clopidogrel bisulfate, cloricromen, dabigatran etexilate, darexaban, dalteparin, dalteparin sodium, defibrotide, dicumarol, diphenadione, dipyridamole, ditazole, desirudin, edoxaban, enoxaparin, enoxaparin sodium, eptifibatide, fondaparinux, fondaparinux sodium, heparin, heparin sodium, heparin calcium, idraparinux, idraparinux sodium, iloprost, indobufen, lepirudin, low molecular weight heparin, melagatran, nadroparin, otamixaban, parnaparin, phenindione, phenprocoumon, prasugrel, picotamide, prostacyclin, ramatroban, reviparin, rivaroxaban, sulodexide, terutroban, terutroban sodium, ticagrelor, ticlopidine, ticlopidine hydrochloride, tinzaparin, tinzaparin sodium, tirofiban, tirofiban hydrochloride, treprostinil, treprostinil sodium, triflusal, vorapaxar, warfarin, warfarin sodium, ximelagatran, salts thereof, solvates thereof, hydrates thereof, and combinations thereof.

8. A method of treating a mantle cell lymphoma (MCL) in a human subject suffering therefrom comprising the step of orally administering, to the human subject, a dose of 100 mg twice daily of a BTK inhibitor, wherein the BTK inhibitor is a compound of Formula (II):

or a pharmaceutically-acceptable salt, hydrate, or solvate thereof.

9. The method of claim 8 , wherein the BTK inhibitor is a compound of Formula (II):

or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the Mantle Cell Lymphoma (MCL) increases monocytes and NK cells in peripheral blood after treatment with Formula (II) for a period selected from the group consisting of about 14 days, about 28 days, and about 56 days.

11. The method of claim 9 , wherein the MCL is selected from the group consisting of mantle zone MCL, nodular MCL, diffuse MCL, and blastoid MCL.

12. The method of claim 9 , further comprising the step of administering a therapeutically effective dose of an anti-CD20 antibody selected from the group consisting of rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, ibritumomab, and fragments, derivatives, conjugates, variants, radioisotope-labeled complexes, and biosimilars thereof.

13. The method of claim 9 , further comprising the step of administering a therapeutically effective dose of an anticoagulant or antiplatelet active pharmaceutical ingredient.

14. The method of claim 13 , wherein the anticoagulant or antiplatelet active pharmaceutical ingredient is selected from the group consisting of acenocoumarol, anagrelide, anagrelide hydrochloride, abciximab, aloxiprin, antithrombin, apixaban, argatroban, aspirin, aspirin with extended-release dipyridamole, beraprost, betrixaban, bivalirudin, carbasalate calcium, cilostazol, clopidogrel, clopidogrel bisulfate, cloricromen, dabigatran etexilate, darexaban, dalteparin, dalteparin sodium, defibrotide, dicumarol, diphenadione, dipyridamole, ditazole, desirudin, edoxaban, enoxaparin, enoxaparin sodium, eptifibatide, fondaparinux, fondaparinux sodium, heparin, heparin sodium, heparin calcium, idraparinux, idraparinux sodium, iloprost, indobufen, lepirudin, low molecular weight heparin, melagatran, nadroparin, otamixaban, parnaparin, phenindione, phenprocoumon, prasugrel, picotamide, prostacyclin, ramatroban, reviparin, rivaroxaban, sulodexide, terutroban, terutroban sodium, ticagrelor, ticlopidine, ticlopidine hydrochloride, tinzaparin, tinzaparin sodium, tirofiban, tirofiban hydrochloride, treprostinil, treprostinil sodium, triflusal, vorapaxar, warfarin, warfarin sodium, ximelagatran, salts thereof, solvates thereof, hydrates thereof, and combinations thereof.

15. The method of claim 2 , the method comprising treating chronic lymphocytic leukemia (CLL) in a human subject suffering from CLL.

16. The method of claim 2 , the method comprising treating small lymphocytic leukemia (SLL) in a human subject suffering from SLL.

17. The method of claim 2 , wherein the free form of the compound of Formula (II) is administered to the human subject.

18. The method of claim 2 , wherein the pharmaceutically acceptable salt of the compound of Formula (II) is administered to the human subject.

19. The method of claim 9 , wherein the free form of the compound of Formula (II) is administered to the human subject.

20. The method of claim 9 , wherein the pharmaceutically acceptable salt of the compound of Formula (II) is administered to the human subject.

Assignees

• Acerta Pharma Bv

Inventors

• Hamdy Ahmed
• Rothbaum Wayne
• Izumi Raquel
• Lannutti Brian
• Covey Todd
• Ulrich roger
• Johnson Dave
• Barf Tjeerd
• Kaptein Allard

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title